Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary arterial hypertension (PAH). Our pipeline is focused on the development of two product candidates using our PRINT® Technology platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain.


Morrisville, NC, USA

Liquidia Corporation

Sovereign's Capital primarily focuses on Healthcare, IT, and Consumer Products & Services - industries that will benefit from the rapidly expanding middle class and are under-represented in the public markets in Southeast Asia. Our fund aligns deep expertise among its principals and advisers in these focus areas.

Portfolio Company Careers